Needham analyst Michael Matson has maintained their neutral stance on ZBH stock, giving a Hold rating on January 30.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Michael Matson has given his Hold rating due to a combination of factors affecting Zimmer Biomet Holdings. Despite the company exceeding revenue and EPS expectations in the fourth quarter of 2024, the guidance for 2025 revenue and EPS is below market consensus, which poses a concern for future growth.
While there has been an improvement in constant currency revenue growth, driven by mid to high-single-digit increases in certain product areas, Zimmer Biomet is faced with challenges such as fewer selling days, adverse currency impacts, and strategic investments that are expected to limit EPS growth. Additionally, the company is experiencing a loss in market share across key segments, with further potential dilution from the Paragon 28 acquisition not yet reflected in current guidance. These factors contribute to the decision to maintain a Hold rating, indicating a cautious outlook for the stock.
According to TipRanks, Matson is an analyst with an average return of -4.0% and a 41.57% success rate. Matson covers the Healthcare sector, focusing on stocks such as Hologic, Boston Scientific, and Haemonetics.
In another report released on January 30, Canaccord Genuity also maintained a Hold rating on the stock with a $115.00 price target.